Evidence map›Paper›PMID 29725582›Full record

ArticleJournal of clinical & translational endocrinology2018

Circulating thyrotropin is upregulated by estradiol.

Salvatore Benvenga, Flavia Di Bari, Roberta Granese, Irene Borrielli, Grazia Giorgianni, Loredana Grasso, Maria Le Donne, Roberto Vita, Alessandro Antonelli

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Sex Bias in Differentiated Thyroid Cancer.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Salvatore BenvengaDepartment of Clinical and Experimental Medicine, Section of Endocrinology, University of Messina, 98125 Messina, Italy.
Flavia Di BariDepartment of Clinical and Experimental Medicine, Section of Endocrinology, University of Messina, 98125 Messina, Italy.
Roberta GraneseDepartment of Obstetrics and Gynecology, University Hospital G. Martino, 98125 Messina, Italy.
Irene BorrielliDepartment of Obstetrics and Gynecology, University Hospital G. Martino, 98125 Messina, Italy.
Grazia GiorgianniService of Immunometry and Laboratory Diagnosis, University Hospital G. Martino, 98125 Messina, Italy.
Loredana GrassoService of Immunometry and Laboratory Diagnosis, University Hospital G. Martino, 98125 Messina, Italy.
Maria Le DonneDepartment of Obstetrics and Gynecology, University Hospital G. Martino, 98125 Messina, Italy.
Roberto VitaDepartment of Clinical and Experimental Medicine, Section of Endocrinology, University of Messina, 98125 Messina, Italy.
Alessandro AntonelliDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
University of Messina · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After encountering two women with serum thyrotropin (TSH) levels greater in periovulatory phase than in other days of the menstrual cycle, we hypothesized that TSH levels could be sensitive to changes in circulating estrogens in women. The objective of this study was to evaluate whether serum TSH increases after an induced acute increase of serum estradiol, and compare serum TSH increase with that of prolactin (PRL) which is a classic estradiol-upregulated pituitary hormone. In this retrospective study, we resorted to stored frozen sera from 55 women who had undergone the GnRH agonist (buserelin)-acute stimulation test of ovarian steroidogenesis. This test, that is preceded by dexamethasone administration to suppress adrenal steroidogenesis, had been performed to show an increased buserelin-stimulated response of 17-hydroxyprogesterone, a response that is frequent in polycystic ovary syndrome. Fifty-five women had enough serum volume at pertinent times (first observation early in the follicular phase and all times of the test) to permit assay of serum estradiol, TSH and PRL. Before dexamethasone administration, estradiol averaged 26.4 ± 15.5 pg/ml (reference range 23-139, follicular phase), TSH 1.78 ± 0.86 mU/L (reference range 0.3-4.2) and PRL 409.4 ± 356 mU/L (reference range 70.8-556) (mean ± SD). Serum estradiol, TSH and PRL averaged 47.2 ± 27 pg/ml, 0.77 ± 0.48 mU/L and 246.4 ± 206.8 mU/L just prior to the buserelin injection, but they peaked at 253.4 ± 113.5 pg/ml (nv 83-495, midcycle), 3.30 ± 1.65 mU/L and 540.3 ± 695.2 mU/L after injection. The responses to buserelin of estradiol, TSH and PRL were of wide magnitude. There was a significant correlation between TSH peak and serum estradiol peak, betweeen AUC0-24 h-TSH and AUC0-24 h-estradiol, or between PRL peak and estradiol peak and AUC0-24 h -PRL and AUC0-24 h-estradiol in only a subgroup of women. Therefore, women with estradiol-dependent increase in serum TSH do exist. Reference bands of serum TSH dependent on the phases of the menstrual cycle should be available.

Indexed as

17-OHPg, 17-hydroxyprogesteroneAUC, area under the curveBuserelinE2, estradiolEstradiolFSH, follicle-stimulating hormoneFT3, free T3GnRH, gonadotropin-releasing hormoneLH, luteinizing hormoneMenstrual cyclePCOS, polycystic ovary syndromePolycystic ovary syndromePRL, prolactinProlactinT3, triiodothyronineT4, thyroxineThyrotropinTRH, TSH-releasing hormoneTSH, thyrotropin

Identifiers

PMID29725582
PMCPMC5928282
OpenAlexW2787683372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.